Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

International, Prospective, Open-label, Multicenter, Pharmacoepidemiological Study to Determine Predictors of Clinical Outcomes in Chemotherapy-treated Cancer Patients at Risk for Febrile Neutropenia and Treated Prophylactically With Filgrastim Biosimilar.

NCT01459653 is registered in ClinicalTrials.gov with Sandoz as lead sponsor.

NCT NCT01459653
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01459653 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
International, Prospective, Open-label, Multicenter, Pharmacoepidemiological Study to Determine Predictors of Clinical Outcomes in Chemotherapy-treated Cancer Patients at Risk for Febrile Neutropenia and Treated Prophylactically With Filgrastim Biosimilar.
Lead sponsor
Sandoz
Phase
Observational
Overall status
Completed
Start date
March 31, 2010
Completion date
August 31, 2013
Enrollment
1,496 (actual)
Sites
117

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphoma, bladder cancer, breast cancer, cancer, febrile neutropenia, lung cancer, multiple myeloma, ovarian cancer, prostate cancer